Search research articles
Contact Us
Filters
Showing results (201-210 of 247) with videos related to
Page
of 25
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 11, 2013
Consistent global approach on reporting of colistin doses to promote safe and effective use
Roger L Nation, Jian Li, Otto Cars, et al.
Antimicrobial Agents and Chemotherapy
|
April 22, 2015
In memoriam: William A. Craig
Ursula Theuretzbacher, Paul G Ambrose, Alasdair P MacGowan, et al.
The Journal of Antimicrobial Chemotherapy
|
August 6, 2016
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies
Gauri G Rao, Neang S Ly, Jürgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy
|
February 22, 2018
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling
Rajbharan Yadav, Kate E Rogers, Phillip J Bergen, et al.
The Lancet. Infectious Diseases
|
December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Roger L Nation, Jian Li, Otto Cars, et al.
The Journal of Antimicrobial Chemotherapy
|
April 27, 2017
Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae
Miao Zhao, Zackery P Bulman, Justin R Lenhard, et al.
The Journal of Antimicrobial Chemotherapy
|
March 24, 2017
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity
Justin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.
Antimicrobial Agents and Chemotherapy
|
March 8, 2017
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model
Phillip J Bergen, Jürgen B Bulitta, Carl M J Kirkpatrick, et al.
Mbio
|
July 27, 2017
Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i><sub>NDM-5</sub>: Preparation for a Postantibiotic Era
Zackery P Bulman, Liang Chen, Thomas J Walsh, et al.
The Journal of Antimicrobial Chemotherapy
|
November 27, 2012
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis
Ana M Sandri, Cornelia B Landersdorfer, Jovan Jacob, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 247) with videos related to
Sort By:
Page
of 25
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 11, 2013
Consistent global approach on reporting of colistin doses to promote safe and effective use
Roger L Nation, Jian Li, Otto Cars, et al.
Antimicrobial Agents and Chemotherapy
|
April 22, 2015
In memoriam: William A. Craig
Ursula Theuretzbacher, Paul G Ambrose, Alasdair P MacGowan, et al.
The Journal of Antimicrobial Chemotherapy
|
August 6, 2016
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies
Gauri G Rao, Neang S Ly, Jürgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy
|
February 22, 2018
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling
Rajbharan Yadav, Kate E Rogers, Phillip J Bergen, et al.
The Lancet. Infectious Diseases
|
December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Roger L Nation, Jian Li, Otto Cars, et al.
The Journal of Antimicrobial Chemotherapy
|
April 27, 2017
Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae
Miao Zhao, Zackery P Bulman, Justin R Lenhard, et al.
The Journal of Antimicrobial Chemotherapy
|
March 24, 2017
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity
Justin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.
Antimicrobial Agents and Chemotherapy
|
March 8, 2017
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model
Phillip J Bergen, Jürgen B Bulitta, Carl M J Kirkpatrick, et al.
Mbio
|
July 27, 2017
Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i><sub>NDM-5</sub>: Preparation for a Postantibiotic Era
Zackery P Bulman, Liang Chen, Thomas J Walsh, et al.
The Journal of Antimicrobial Chemotherapy
|
November 27, 2012
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis
Ana M Sandri, Cornelia B Landersdorfer, Jovan Jacob, et al.
Page
of 25